Lung Cancer
Medical Oncology

Get to Know Dr. Jhanelle Gray

Dr. Jhanelle Gray treats patients with pleural mesothelioma and other thoracic malignancies as part of a multidisciplinary program at the H. Lee Moffitt Cancer Center.

Her research focus today is evaluating new molecular targets and biomarkers in lung cancer to better personalize treatment and reduce chemotherapy resistance, which has been a particular problem with mesothelioma.

As part of the research team, Gray works closely with thoracic surgeon Dr. Jacques Fontaine, head of the mesothelioma program at Moffitt, along with radiologists, pathologists and epidemiologists in the Department of Thoracic Oncology.

She has played a major role in Moffitt’s leadership as a cancer center, turning translational research into novel clinical advances that improve quality of life and outcomes for patients going through mesothelioma treatment.

Gray began practicing medicine in 2007. She serves as principal investigator of several clinical trials involving lung cancer.

Specialties of Dr. Jhanelle Gray

Dr. Jhanelle Gray’s Experience and Medical Education

  • H. Lee Moffitt Cancer Center
  • H. Lee Moffitt Cancer Center & Research Institute (Fellowship)
  • New York Presbyterian Hospital (Residency)
  • Weill Medical College of Cornell University (M.D.)

Dr. Jhanelle Gray’s Awards and Certifications

  • Board certified in medical oncology
  • Board certified in hematology
  • Healthgrades Honor Roll

Publications of Dr. Jhanelle Gray

  • Perez, B.A. et al. (2020, September 28). A Prospective Single Arm Phase I/II Study: Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics.
  • Gray, J.E. et al. (2020, February 15). Three-Year Overall Survival with Durvalumab after Chemotherapy in Stage III NSCLC — Update from PACIFIC. Journal of Thoracic Oncology.
  • Gray, J.E. et al. (2019, November 25). Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer. Clinical Cancer Research.
  • Gray, J.E. et al. (2019, November 15). Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research.